Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab

PURPOSE: Blockade of the programmed death-1 inhibitory cell-surface molecule on immune cells using the fully human immunoglobulin G4 antibody nivolumab mediates tumor regression in a portion of patients with advanced treatment-refractory solid tumors. We report clinical activity, survival, and long-...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: McDermott, David F., Drake, Charles G., Sznol, Mario, Choueiri, Toni K., Powderly, John D., Smith, David C., Brahmer, Julie R., Carvajal, Richard D., Hammers, Hans J., Puzanov, Igor, Hodi, F. Stephen, Kluger, Harriet M., Topalian, Suzanne L., Pardoll, Drew M., Wigginton, Jon M., Kollia, Georgia D., Gupta, Ashok, McDonald, Dan, Sankar, Vindira, Sosman, Jeffrey A., Atkins, Michael B.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2015
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4517051/
https://ncbi.nlm.nih.gov/pubmed/25800770
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.58.1041
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados